Danaher Corporation
DHR Healthcare Diagnostics & Research
Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024. In the quarter to June 2026, revenue grew 5.54%, EPS grew 59.7%, free cash flow grew 15.6% and total debt rose 49.2%, each against the same quarter a year earlier. Member of the S&P 500.
Follow DHR
Danaher Corporation (DHR) EV/Sales
As of 16 October 2026, Danaher Corporation (DHR) trades at a EV/Sales of 7.3×. Over the past ten years it has ranged from 2.0× (September 2015) to 9.4× (August 2024); the current reading is higher than 73% of that period. That is above the Diagnostics & Research industry median of 5.5× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.2× | (5.11%) |
| FY2024 | 7.6× | (1.32%) |
| FY2023 | 7.7× | 12.80% |
| FY2022 | 6.8× | (25.83%) |
| FY2021 | 9.2× | 32.83% |
| FY2020 | 6.9× | 25.36% |
| FY2019 | 5.5× | 29.03% |
| FY2018 | 4.3× | (0.47%) |
| FY2017 | 4.3× | 27.37% |
| FY2016 | 3.4× | (11.12%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 6.2× | 4.81% |
| Mar 2026 | 5.9× | (18.15%) |
| Dec 2025 | 7.2× | 11.90% |
| Sep 2025 | 6.4× | (0.56%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IQV IQVIA Holdings Inc. compare | 3.4× |
| TMO Thermo Fisher Scientific Inc. compare | 6.3× |
| A Agilent Technologies, Inc. compare | 6.9× |
| DHR Danaher Corporation | 7.3× |
| MTD Mettler-Toledo International, Inc. compare | 8.4× |
| ILMN Illumina, Inc. compare | 9.0× |
| IDXX IDEXX Laboratories, Inc. compare | 9.8× |
| WAT Waters Corporation compare | 10.2× |
| NTRA Natera, Inc. compare | 20.5× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on DHR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement